Loading clinical trials...

UNKNOWNNA

Digitalized Management Exploration for Gestational Diabetes Mellitus in China

Comparison of Conventional Mode and Combined Digitalized Mode of Management for Gestational Diabetes Mellitus in China

NCT05003154•Women's Hospital School Of Medicine Zhejiang University

Summary

Gestational diabetes mellitus (GDM) can lead to adverse perinatal and long-term outcomes, and it is so important to manage this disease in pregnancy. Digitalized managements have been proved economical and effective in some chronic diseases like type II diabetes mellitus. The purpose of the current study was to develop and evaluate a digitalized mode for GDM management using mobile healthcare and some wearable devices. Subjects were randomly divided into a conventional management group and combined digitalized management group after diagnosed with GDM during 24-28 weeks of gestation. The conventional mangement group received conventional GDM management and could freely use the mobile healthcare application. The mobile management group received digitalized healthcare services from artificial intelligence under the supervision of obstetricians, in addition to conventional management. The effectiveness of digitalized management were evaluated mainly through the result values of the labotatory tests related to blood glucose controlling and perinatal outcomes.

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. The age of 18-45 years, single pregnancy, Han nationality;
•2. GDM diagnosed between 24 to 28 weeks of gestation, either of the following: fasting plasma glucose ≥5.1 mmol/L, 60-minute plasma glucose ≥10.0 mmol/L, 120-minute plasma glucose ≥8.5 mmol/L, during a 75g oral glucose tolerance test (OGTT).
•3. Plan to deliver the baby in Women's Hospital School Of Medicine Zhejiang University;
•4. Can operate mobile phones and related software;
•5. Voluntary participation in this study;
•6. Education background: junior high school or above.

Exclusion Criteria

•1. Type I or II or other non GDM diabetes mellitus;
•2. Severe pregnancy complications or complications: such as malignant tumor, preeclampsia, severe intrahepatic cholestasis of pregnancy syndrome, pregnancy with antiphospholipid antibody syndrome, severe anemia (hemoglobin\<90g/L, etc.), cardiac insufficiency cardiovascular disease (such as myocardial infarction, heart failure, pulmonary hypertension, stroke history, coronary heart disease, valvular heart disease, etc.), stroke (moderate), liver disease (such as hepatic insufficiency, acute viral hepatitis, etc.), lung disease (such as restrictive lung disease, emphysema, liver cirrhosis, pulmonary heart disease, etc.), kidney disease (such as nephrotic syndrome, chronic nephritis, renal insufficiency, etc.), chronic hypertension, thyroid disease (such as hyperthyroidism, hypothyroidism, thyroiditis, etc.), other endocrine diseases (such as Cushing's syndrome Acromegaly, venous or arterial thromboembolic diseases, rheumatic immune diseases, etc;
•3. The combined conditions that may affect the diet exercise therapy include severe food allergy, dyskinesia (physical disability), history of bariatric surgery, major gastrointestinal diseases (such as gastrointestinal bleeding, inflammatory bowel disease, gastrointestinal tumor, active stage of peptic ulcer, chronic intestinal obstruction, etc.), restrictive lung disease, history of two or more adverse abortions, placenta previa, repeated and persistent bleeding threatened abortion, threatened premature birth, hyperemesis gravidarum, vegetarians, etc;
•4. Other conditions: such as mental disorders, cervical incompetence, genital tract deformity, etc;
•5. Patients who are taking medicine that may affect glucose metabolism, such as ritodrine, prednisone, etc;
•6. Patients who are participating in other clinical studies;
•7. The researchers believe patients who are not suitable for this study

Locations (1)

Danqing Chen

Hangzhou, Zhejiang, China

Key Dates

Start Date

September 1, 2021

Primary Completion Date

January 1, 2024

Completion Date

August 1, 2024

Last Updated

August 12, 2021

Enrollment

ESTIMATED participants

Conditions

Gestational Diabetes Mellitus in Pregnancy

Interventions

Digitalized management

OTHER

Contacts

Danqing Chen, PhD

CONTACT

+860571-87061501 chendq@zju.edu.cn

Menglin Zhou, MD

CONTACT

+8613738008135 marlin_zhou@zju.edu.cn

Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes

NCT06948825

Weight LossGestational Diabetes Mellitus in Pregnancy+1 more

View study

RECRUITINGNA

Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia

NCT06643351

Gestational Diabetes Mellitus in PregnancyPregestational Diabetes Mellitus+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 12, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Digitalized Management Exploration for Gestational Diabetes Mellitus in China

Inclusion Criteria

Exclusion Criteria

Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes

Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia

MIRACLE of LIFE Study

Self-Administered 2-Hour Oral Glucose Tolerance Test

Effects of Rhythm-Based Music on Pregnancies With Gestational Diabetes

D-chiro Inositol in Prevention of Gestational Diabetes Mellitus in China